# Halia Therapeutics

**Type:** venture
**Status:** Draft
**Confidence:** Medium
**Focus:** drug discovery, inflammation, inflammaging, NLRP3 inflammasome, clinical-stage biopharma, life sciences
**Stage:** Private, clinical-stage; Phase 2a data reported 2025
**Location:** Lehi, UT
**Updated:** 2026-06-18
**Needs-reviewed:** 2026-06-18
**Hero:** https://picsum.photos/seed/halia-therapeutics-nek7-inflammasome-2026/1600/1100
**Pull:** *Trying to treat the inflammation underneath aging, not just one disease at a time.*

## Summary

Halia Therapeutics is a Lehi, Utah clinical-stage biopharmaceutical company developing drugs that target chronic inflammation — specifically the NLRP3 inflammasome pathway implicated in aging and in inflammation-driven disease. Its lead candidate, ofirnoflast (HT-6184), is described as a first-in-class oral allosteric NEK7 inhibitor. The company is led by founder and academic drug-discovery scientist Dave Bearss. [source:halia-therapeutics-official-website]

For the Great Work Utah wiki, Halia is one of the most scientifically ambitious life-sciences bets in the state: a Utah-based attempt to drug a root mechanism of aging, with real clinical data rather than only a mechanism story.

## Impact

"Inflammaging" is the idea that aging is driven in part by sustained low-grade inflammation that undermines tissue repair and contributes to many late-life diseases. NLRP3 is a well-validated node in that inflammatory cascade but has been notoriously hard to drug directly — several direct NLRP3 inhibitors failed on toxicity. Halia's approach blocks NEK7's interaction with NLRP3 upstream, via an allosteric mechanism the company argues is more selective.

If that selectivity holds in humans and the benefit translates across disease areas, the mechanism becomes a platform rather than a single-product story. That is the upside; it remains unproven beyond early-stage data.

## What They Are Building

Ofirnoflast (HT-6184) is being studied first in lower-risk myelodysplastic syndrome (MDS), a blood disorder with an inflammatory component and few good options for patients with symptomatic anemia. At the American Society of Hematology (ASH) 2025 annual meeting, Halia reported Phase 2a results from a Stage 1 efficacy population of 18 evaluable patients: a 72% hematologic improvement–erythroid (HI-E) response rate after at least 16 weeks, including high response rates in ESA-refractory and ESA-intolerant patients, with no treatment-related serious adverse events and no Grade 3 or higher related events reported. The trial (NCT07052006) was listed as active, not recruiting, with a completion date in 2026. [source:halia-therapeutics-official-website]

Beyond MDS, the company has described a broader pipeline, including a planned program combining HT-6184 with semaglutide for obesity and type 2 diabetes, and a separate neuroinflammation candidate (HT-4253) in earlier clinical work.

## What They Need Now

Likely needs for a company at this stage include drug-discovery scientists, medicinal chemists, clinical pharmacologists, translational and clinical-operations staff, regulatory leaders experienced in oncology and hematology trials, and the capital to move from Phase 2a toward larger, confirmatory studies. A relatively small team for the scope of the program means individual scientists and operators carry unusually high leverage.

For talent matching, Halia fits scientists who want to work on aging and inflammation biology with genuine clinical traction, in Utah, and who are comfortable with the binary risk profile of a clinical-stage drug program.

## Who Could Help

Useful helpers include FDA and clinical-regulatory counsel, clinical-trial design and biostatistics advisors, life-sciences venture and crossover investors comfortable with clinical risk, and CDMO and manufacturing partners for small-molecule scale-up. Investor and board relationships that can fund a Phase 3-scale program would be the highest-value connections.

## Utah Context

Halia anchors a small but serious clinical-stage drug-discovery presence in the Lehi / Silicon Slopes corridor, a region better known for software than for therapeutics. Founder Dave Bearss also has deep ties to Utah's broader translational ecosystem — he has been publicly associated with the University of Utah's therapeutics-accelerator work — which links Halia to the same academic drug-discovery community that surrounds the [Huntsman Cancer Institute](huntsman-cancer-institute.md). That overlap makes Halia a useful case study in how Utah academic science turns into venture-backed drug programs.

## Evidence

- [Source: Halia Therapeutics Official Website and ASH 2025 Phase 2a Disclosure](halia-therapeutics-official-website.md)

## Open Questions

- The total amount raised and current financing stage are not confirmed from a primary source in this pass. A frequently cited "Series C, ~$56.3M raised" figure comes from secondary coverage and should be verified before use in a recommendation.
- Phase 2a results are promising but early; most candidates that look strong at Phase 2a do not survive larger trials. The MDS-to-broader-aging leap currently rests on mechanism, not outcome data.
- Current headcount, named investors, and whether founders retain control are not confirmed here.
- Press-release and conference-abstract data are leads, not independent proof; peer-reviewed, fuller datasets would strengthen the efficacy claims.
- Imagery is a deterministic placeholder. A license-cleared lab, team, or molecular-graphic image approved by the company should replace it before this renders as a marquee page.

## See Also

- [Dave Bearss](dave-bearss.md)
- [Huntsman Cancer Institute](huntsman-cancer-institute.md)